GPT and chronic myelogenous leukemia, BCR-ABL1 positive: Contrary to AST, a profound impact with 63.1%, 59.1%, 64.3%, and 63.4% reduced serum ALT levels were assessed in SO1%, SO2%, OSO1%, and OSO2% injected groups, respectively, concerning only CML injected group (Figure 6B).